By Nate Raymond NEW YORK (Reuters) - Former pharmaceutical executive Martin Shkreli suffered a roughly $40 million drop in the value of a trading account used to secure his bail following his arrest on securities fraud charges, a U.S. prosecutor said on Wednesday. At a hearing in federal court in Brooklyn, Assistant U.S. Attorney Winston Paes said the account contained mostly shares of KaloBios Pharmaceuticals Inc , a drug company that Shkreli briefly ran. Paes told U.S. District Judge Kiyo Matsumoto that Shkreli may need to post new assets to secure his $5 million bond, which was issued following the 32-year-old's arrest in December.
The U.S. Justice Department is considering legal changes to combat what it sees as a rising threat from domestic anti-government extremists, senior officials told Reuters, even as it steps up efforts to stop Islamic State-inspired attacks at home. Extremist groups motivated by a range of U.S.-born philosophies present a "clear and present danger," John Carlin, the Justice Department's chief of national security, told Reuters in an interview. Over the past year, the Justice Department has brought charges against domestic extremist suspects accused of attempting to bomb U.S. military bases, kill police officers and fire bomb a school and other buildings in a predominantly Muslim town in New York state.
WASHINGTON (AP) — Pharmaceutical chief Martin Shkreli refused to testify Thursday in an appearance before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired.
By David Ingram and Sarah N. Lynch NEW YORK/WASHINGTON (Reuters) - Martin Shkreli, the former drug executive who raised the price of a lifesaving medicine by 5,000 percent, is set to appear as a witness at a congressional hearing on Thursday but is unlikely to answer lawmakers' questions about price spikes. Shkreli, 32, sparked outrage last year among patients, medical societies and Democratic presidential front-runner Hillary Clinton after his company Turing Pharmaceuticals raised the price of 62-year-old Daraprim to $750 a pill from $13.50. The U.S. House Committee on Oversight and Government Reform is scheduled to hold a hearing on drug prices at 9 a.m. EST (1400 GMT), with Shkreli and others from the pharmaceutical industry as witnesses.